December 2015, Vol. 4, No. 6
Personalized Medicine in Oncology: Disseminating Essential Information
On behalf of all of us at Personalized Medicine in Oncology (PMO), I’d like to offer our warmest wishes to you this holiday season and our thanks for your loyal readership throughout 2015. Over this past year, we have witnessed advances in our knowledge of tumor biology, biomarkers, and immunotherapies that will ultimately improve our ability to effectively and safely treat patients with cancer.
With these advances, our editorial staff has added departments and enhanced existing ones to improve dissemination of this essential information. These include:
- Interview with the Innovators Series: In each issue, we speak with people making a difference in the field of personalized medicine. From leading researchers and novel diagnostic companies to policy makers and patient organizations, these interviews provide insights to the trends in precision medicine
- Genetic Counseling Column: 2015 saw the launch of our newest department authored by editorial board member Cristi Radford, MS, CGC, of the Moffitt Cancer Center. Ms Radford will address cutting-edge topics in this expanding field
- The Last Word: PMO is a proud partner of the Personalized Medicine Coalition (PMC) and is pleased to host a regular column by the President of the PMC, Edward Abrahams, PhD. Dr Abrahams brings expertise in the policy trends affecting our ability to provide personalized care to our patients
- PersonalizedMedOnc.com: An invaluable resource to our readers, our website includes articles from the journal as well as breaking news stories, conference correspondent highlights, special issues, and videos. I strongly encourage you to subscribe.
It is our continuing hope that our comprehensive services benefit you and ultimately your patients. Thank you for your readership and all the best to you in 2016.
Al B. Benson III, MD, FACP, FASCO
Coeditor in Chief
Personalized Medicine in Oncology
Prostate cancer remains one of the major health issues for men worldwide and is the second leading cause of cancer-related death in males in the United States…
Patients with advanced neuroendocrine tumors (NETs) have 2 promising new treatment options, according to separate phase 3 studies presented as late-breakers at the 2015 European Cancer Congress. The NETTER-1 trial evaluated the radiopharmaceutical agent 177Lu-DOTATATE in NETs confined to the midgut, while RADIANT-4 evaluated the mTOR inhibitor everolimus in patients [ Read More ]